EU watchdog to assess availability of drugs made at Catalent sites sold to Novo

In this article:

FRANKFURT, Feb 7 (Reuters) - The European Union's drugs regulator said on Wednesday it will assess the impact on the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk. (Reporting by Ludwig Burger)

Advertisement